ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2154

An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin

Elizabeth Bundschuh1, Rebecca Fine2, Miruna Carnaru3, Sanchit Kumar4, Francis Perry Wilson2, Alyssa Williams1, Shannon Teaw4, Ian Odell4 and Monique Hinchcliff5, 1Yale University, New Haven, CT, 2Yale School of Medicine, New Haven, CT, 3Hartford Healthcare Medical Group, Rocky Hill, CT, 4Yale University School of Medicine, New Haven, CT, 5Yale School of Medicine, Westport, CT

Meeting: ACR Convergence 2022

Keywords: Dermatology, immunology, Protein Kinase, Scleroderma

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Systemic Sclerosis and Related Disorders – Clinical Poster III

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Receptor tyrosine kinases (RTK) such as epidermal growth factor receptor (EGFR) and others including PDGFRs, FGFRs, and VEGFRs are implicated in systemic sclerosis (SSc) skin fibrosis. We previously identified a subpopulation of fibroblasts that express EGFR and drive SSc skin fibrosis in a multicellular circuit. This study sheds light upon molecular pathways downstream of RTK in fibroblasts that may be important in SSc skin disease.

Methods: Tyrosine phosphoarray analysis (ELISA-based array for 228 analytes; FullMoon Biosystems, Sunnyvale, CA) was conducted on fresh skin biopsies from three SSc patients and matched healthy controls (HC). Skin biopsies from 13 SSc patients and 18 HCs were subjected to immunohistochemical staining for EGFR, pEGFR and downstream targets including pSTAT4, STAT4, STAT1, SRC, pS6, S6, ERK1/2, pAKT and AKT (Fig.1). One blinded assessor counted positively stained, non-vascular, spindle-shaped (i.e. fibroblasts) dermal cells in 10 randomly chosen fields of view/slide at 40x magnification. A logistic regression model was developed where an increase in stained cells/field increases the likelihood a skin sample is from a SSc vs. HC subject.

Results: SSc vs. HC showed increased phosphorylation of EphA3, PDGFRb, C-kit, FLT3, BLNK, IL-4, Vinculin, TFII-1, CD19, and ALK and decreased phosphorylation of JAK1, SRC, SLP-76, CrkII, Gab2, JNK1, LCK, STAT4) as assessed by the phosphoarray (Fig.2). Immunohistochemical analysis demonstrated increased STAT4 (OR = 1.04), STAT1 (OR = 1.10), pS6 (OR = 1.78), S6 (OR = 1.28), and pEGFR (OR = 1.10) when compared with HC (Fig.3).

Conclusion: In addition to EGFR and PDGFR that have been shown to be important in SSc skin disease, the phosphoarray results newly identified elevated p-EphA3, an RTK expressed by fibroblasts with roles in various cancers and idiopathic pulmonary fibrosis, in SSc vs. HC skin. The mTOR and STAT1 pathways appear upregulated in SSc vs. HC skin. In the future, functional experiments will be conducted to further elucidate the involvement of specific RTKs and downstream pathways in SSc skin.

Supporting image 1

Figure 1. RTKs and downstream pathways in SSc skin.

Supporting image 2

Figure 2. A. Abridged list of 10 (out of 228) proteins with increased phosphorylation in SSc vs. HC skin. *Relative phosphorylation level (SSc/HC) > 2. B. Abridged list of 8 proteins with decreased phosphorylation in SSc vs. HC skin. *Relative phosphorylation level (SSc/HC) < 0.5.

Supporting image 3

Figure 3. A. Odds ratio and 95% confidence interval for IHC proteins. *p < 0.05, CI > 1.0.


Disclosures: E. Bundschuh, None; R. Fine, None; M. Carnaru, None; S. Kumar, None; F. Wilson, Amgen, Boeringher-Ingelheim, Vifor Pharma, Whoop, AstraZeneca; A. Williams, None; S. Teaw, None; I. Odell, AbbVie/Abbott; M. Hinchcliff, Kadmon.

To cite this abstract in AMA style:

Bundschuh E, Fine R, Carnaru M, Kumar S, Wilson F, Williams A, Teaw S, Odell I, Hinchcliff M. An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/an-exploratory-phosphoproteomic-and-immunohistochemical-analysis-of-receptor-tyrosine-kinases-and-downstream-signaling-pathways-in-systemic-sclerosis-skin/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-exploratory-phosphoproteomic-and-immunohistochemical-analysis-of-receptor-tyrosine-kinases-and-downstream-signaling-pathways-in-systemic-sclerosis-skin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology